# Julia M. Hofstra

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/julia-m-hofstra/

## Facts

| Field | Value |
| --- | --- |
| Citations | 4,745 |
| Field | Renal Diseases and Glomerulopathies |
| h-index | 34 |
| i10-index | 40 |
| OpenAlex ID | https://openalex.org/A5051807668 |
| Works | 60 |

## Researcher papers

- [Risk HLA-DQA1 and PLA <sub>2</sub> R1 Alleles in Idiopathic Membranous Nephropathy](https://scholariq.org/papers/risk-hla-dqa1-and-pla-sub-2-sub-r1-alleles-in-idiopathic-membranous-nephropathy/)
- [COVID-19-related mortality in kidney transplant and dialysis patients: results of the ERACODA collaboration](https://scholariq.org/papers/covid-19-related-mortality-in-kidney-transplant-and-dialysis-patients-results-of/)
- [Anti-Phospholipase A2 Receptor Antibodies Correlate with Clinical Status in Idiopathic Membranous Nephropathy](https://scholariq.org/papers/anti-phospholipase-a2-receptor-antibodies-correlate-with-clinical-status-in/)
- [Antiphospholipase A2 Receptor Antibody Titer and Subclass in Idiopathic Membranous Nephropathy](https://scholariq.org/papers/antiphospholipase-a2-receptor-antibody-titer-and-subclass-in-idiopathic/)
- [Neutrophil Extracellular Traps Drive Endothelial-to-Mesenchymal Transition](https://scholariq.org/papers/neutrophil-extracellular-traps-drive-endothelial-to-mesenchymal-transition/)
- [The STARMEN trial indicates that alternating treatment with corticosteroids and cyclophosphamide is superior to sequential treatment with tacrolimus and rituximab in primary membranous nephropathy](https://scholariq.org/papers/the-starmen-trial-indicates-that-alternating-treatment-with-corticosteroids-and/)
- [The genetic architecture of membranous nephropathy and its potential to improve non-invasive diagnosis](https://scholariq.org/papers/the-genetic-architecture-of-membranous-nephropathy-and-its-potential-to-improve/)
- [Safety of Rituximab Compared with Steroids and Cyclophosphamide for Idiopathic Membranous Nephropathy](https://scholariq.org/papers/safety-of-rituximab-compared-with-steroids-and-cyclophosphamide-for-idiopathic/)
- [Association of Anti-PLA2R Antibodies with Outcomes after Immunosuppressive Therapy in Idiopathic Membranous Nephropathy](https://scholariq.org/papers/association-of-anti-pla2r-antibodies-with-outcomes-after-immunosuppressive/)
- [High prevalence of hypogonadotropic hypogonadism in men referred for obesity treatment.](https://scholariq.org/papers/high-prevalence-of-hypogonadotropic-hypogonadism-in-men-referred-for-obesity/)
- [Pharmacological treatment of primary membranous nephropathy in 2016](https://scholariq.org/papers/pharmacological-treatment-of-primary-membranous-nephropathy-in-2016/)

## Researcher topics

- [Renal Diseases and Glomerulopathies](https://scholariq.org/topics/renal-diseases-and-glomerulopathies/)
- [Vasculitis and related conditions](https://scholariq.org/topics/vasculitis-and-related-conditions/)
- [Chronic Kidney Disease and Diabetes](https://scholariq.org/topics/chronic-kidney-disease-and-diabetes/)
- [Autoimmune Bullous Skin Diseases](https://scholariq.org/topics/autoimmune-bullous-skin-diseases/)
- [Dialysis and Renal Disease Management](https://scholariq.org/topics/dialysis-and-renal-disease-management/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.